Friederike Beker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Friederike Beker has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Arvind Sehgal
Department of Paediatrics, Monash University, Melbourne, Victoria 3168, Australia
3 shared publicationsPeter G. Davis
Neonatal Services and Newborn Research, The Royal Women’s Hospital, Melbourne, Australia
3 shared publications- Frank Harry Bloomfield
University of Auckland
2 shared publications Peter G Davis
Neonatal Intensive Care Unit and Newborn Research, The Royal Women's Hospital, Melbourne, Victoria, Australia
2 shared publicationsSheryle R. Rogerson
The Royal Women's Hospital, Parkville, Victoria, Australia
2 shared publicationsAh Stam
Department of Neurology, Leiden University Medical Centre, Leiden
1 shared publication
Latest Publications
- Open Access
- 22 April 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-6
Smell and taste of milk during tube feeding of preterm infants: neurodevelopmental follow-up of the randomized TASTE trial, study protocol
Background: The Taste And Smell To Enhance nutrition (TASTE) trial investigated the effects of smell and taste of milk with tube feeding compared to routine care on the growth of preterm infants. There was no difference between groups in growth (weight, head circumference, length) z-scores at discharge from the hospital. Infants in the intervention group had higher head circumference and length z-scores at 36 weeks postmenstrual age, both secondary outcomes. The objective of this follow-up study is to assess 2-year neurodevelopmental and growth outcomes after exposure of preterm infants to the smell and taste of milk with tube feeding compared to routine care. Methods: This is a neurodevelopmental follow-up study of a two-center, placebo-controlled randomized trial. Infants born before 29 weeks postmenstrual age and/or with a birth weight of less than 1250 g were randomized to smell and taste of milk with each tube feed or routine care. The current follow-up assessed the 2-year neurodevelopmental and growth outcomes of participants of the TASTE trial discharged from the hospital (n = 334). The primary outcome is survival free of any major neurodevelopmental impairment comprising any moderate/severe cerebral palsy (Gross Motor Function Classification System score II–V), Bayley Scales of Infant and Toddler Development, Third/Fourth Edition (Bayley-III/Bayley-4) motor, cognitive, or language scores < -2SD, blindness, or deafness at 2 years of age. Other outcomes include death, breastfeeding within the first year, and respiratory support, oral feeding, and anthropometric parameters at 2 years of age. The Human Research Ethics Committees of Mater Misericordiae Limited and the Royal Women’s Hospital approved the TASTE trial including the neurodevelopmental follow-up described in this protocol. Discussion: For patients and their families, the neurodevelopmental outcomes of preterm infants are of utmost importance. Consequently, they should be investigated following any interventional study performed during the newborn period. Furthermore, improved weight gain and head growth in the hospital are associated with better long-term neurodevelopmental outcomes. Smelling and tasting of milk is an uncomplicated and cost-effective intervention that may improve the growth and neurodevelopmental outcomes of preterm infants. Potential limitations affecting this follow-up study, caused by the COVID-19 pandemic, are anticipated and discussed in this protocol. Trial registration: Name of the registry: Australian and New Zealand Clinical Trials Registry; Registration number: ACTRN12617000583347; Registration date: 26 April 2017.
- 22 April 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-6
Open AccessSmell and taste of milk during tube feeding of preterm infants: neurodevelopmental follow-up of the randomized TASTE trial, study protocol
Background: The Taste And Smell To Enhance nutrition (TASTE) trial investigated the effects of smell and taste of milk with tube feeding compared to routine care on the growth of preterm infants. There was no difference between groups in growth (weight, head circumference, length) z-scores at discharge from the hospital. Infants in the intervention group had higher head circumference and length z-scores at 36 weeks postmenstrual age, both secondary outcomes. The objective of this follow-up study is to assess 2-year neurodevelopmental and growth outcomes after exposure of preterm infants to the smell and taste of milk with tube feeding compared to routine care. Methods: This is a neurodevelopmental follow-up study of a two-center, placebo-controlled randomized trial. Infants born before 29 weeks postmenstrual age and/or with a birth weight of less than 1250 g were randomized to smell and taste of milk with each tube feed or routine care. The current follow-up assessed the 2-year neurodevelopmental and growth outcomes of participants of the TASTE trial discharged from the hospital (n = 334). The primary outcome is survival free of any major neurodevelopmental impairment comprising any moderate/severe cerebral palsy (Gross Motor Function Classification System score II–V), Bayley Scales of Infant and Toddler Development, Third/Fourth Edition (Bayley-III/Bayley-4) motor, cognitive, or language scores < -2SD, blindness, or deafness at 2 years of age. Other outcomes include death, breastfeeding within the first year, and respiratory support, oral feeding, and anthropometric parameters at 2 years of age. The Human Research Ethics Committees of Mater Misericordiae Limited and the Royal Women’s Hospital approved the TASTE trial including the neurodevelopmental follow-up described in this protocol. Discussion: For patients and their families, the neurodevelopmental outcomes of preterm infants are of utmost importance. Consequently, they should be investigated following any interventional study performed during the newborn period. Furthermore, improved weight gain and head growth in the hospital are associated with better long-term neurodevelopmental outcomes. Smelling and tasting of milk is an uncomplicated and cost-effective intervention that may improve the growth and neurodevelopmental outcomes of preterm infants. Potential limitations affecting this follow-up study, caused by the COVID-19 pandemic, are anticipated and discussed in this protocol. Trial registration: Name of the registry: Australian and New Zealand Clinical Trials Registry; Registration number: ACTRN12617000583347; Registration date: 26 April 2017.
- 6 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (639) , eaaz8454
Type 2 immune polarization is associated with cardiopulmonary disease in preterm infants
Postnatal maturation of the immune system is poorly understood, as is its impact on illnesses afflicting term or preterm infants, such as bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension. These are both cardiopulmonary inflammatory diseases that cause substantial mortality and morbidity with high treatment costs. Here, we characterized blood samples collected from 51 preterm infants longitudinally at five time points, 20 healthy term infants at birth and age 3 to 16 weeks, and 5 healthy adults. We observed strong associations between type 2 immune polarization in circulating CD3 + CD4 + T cells and cardiopulmonary illness, with odds ratios up to 24. Maternal magnesium sulfate therapy, delayed hepatitis B vaccination, and increasing fetal, but not maternal, chorioamnionitis severity were associated with attenuated type 2 polarization. Blocking type 2 mediators such as interleukin-4 (IL-4), IL-5, IL-13, or signal transducer and activator of transcription 6 (STAT6) in murine neonatal cardiopulmonary disease in vivo prevented changes in cell type composition, increases in IL-1β and IL-13, and losses of pulmonary capillaries, but not gains in larger vessels. Thereby, type 2 blockade ameliorated lung inflammation, protected alveolar and vascular integrity, and confirmed the pathological impact of type 2 cytokines and STAT6. In-depth flow cytometry and single-cell transcriptomics of mouse lungs further revealed complex associations between immune polarization and cardiopulmonary disease. Thus, this work advances knowledge on developmental immunology and its impact on early life disease and identifies multiple therapeutic approaches that may relieve inflammation-driven suffering in the youngest patients.
- 6 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (639) , eaaz8454
Type 2 immune polarization is associated with cardiopulmonary disease in preterm infants
Postnatal maturation of the immune system is poorly understood, as is its impact on illnesses afflicting term or preterm infants, such as bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension. These are both cardiopulmonary inflammatory diseases that cause substantial mortality and morbidity with high treatment costs. Here, we characterized blood samples collected from 51 preterm infants longitudinally at five time points, 20 healthy term infants at birth and age 3 to 16 weeks, and 5 healthy adults. We observed strong associations between type 2 immune polarization in circulating CD3 + CD4 + T cells and cardiopulmonary illness, with odds ratios up to 24. Maternal magnesium sulfate therapy, delayed hepatitis B vaccination, and increasing fetal, but not maternal, chorioamnionitis severity were associated with attenuated type 2 polarization. Blocking type 2 mediators such as interleukin-4 (IL-4), IL-5, IL-13, or signal transducer and activator of transcription 6 (STAT6) in murine neonatal cardiopulmonary disease in vivo prevented changes in cell type composition, increases in IL-1β and IL-13, and losses of pulmonary capillaries, but not gains in larger vessels. Thereby, type 2 blockade ameliorated lung inflammation, protected alveolar and vascular integrity, and confirmed the pathological impact of type 2 cytokines and STAT6. In-depth flow cytometry and single-cell transcriptomics of mouse lungs further revealed complex associations between immune polarization and cardiopulmonary disease. Thus, this work advances knowledge on developmental immunology and its impact on early life disease and identifies multiple therapeutic approaches that may relieve inflammation-driven suffering in the youngest patients.
- Open Access
- 20 November 2019
- Published by Elsevier in The Journal of Pediatrics: X
- Vol. 1, 100009
Neonatal Cardiovascular Function after Antenatal Sildenafil for Severe, Early-Onset Intrauterine Growth Restriction: A Substudy of the STRIDER-NZAus Randomized Placebo-Controlled Trial
- 20 November 2019
- Published by Elsevier in The Journal of Pediatrics: X
- Vol. 1, 100009
Open AccessNeonatal Cardiovascular Function after Antenatal Sildenafil for Severe, Early-Onset Intrauterine Growth Restriction: A Substudy of the STRIDER-NZAus Randomized Placebo-Controlled Trial
- Open Access
The effect of smell and taste of milk during tube feeding of preterm infants (the Taste trial): a protocol for a randomised controlled trial
Introduction Smell and taste of milk are not generally considered when tube feeding preterm infants. Preterm infants have rapid growth, particularly of the brain, and high caloric needs. Enteral feeding is often poorly tolerated which may lead to growth failure and long-term neurodevelopmental impairment. Smell and taste are strong stimulators of digestion and metabolism. We hypothesise that regular smell and taste during tube feeding will improve weight z-scores of very preterm infants at discharge from hospital. Methods and analysis Taste is a randomised, unblinded two-centre trial. Infants born at Ethics and dissemination Human Research Ethics Committees of Mater Misericordiae (trial reference number: HREC/16/MHS/112) and the Royal Women’s Hospital (trial reference number: 17/21) last approved the trial protocol (version 4.2; Date: 18 December 2018) and recruitment commenced in May 2017 and November 2017, respectively. The trial results will be published in a peer-reviewed journal and will be presented at national and international conferences. Trial registration number ACTRN12617000583347.
Open AccessThe effect of smell and taste of milk during tube feeding of preterm infants (the Taste trial): a protocol for a randomised controlled trial
Introduction Smell and taste of milk are not generally considered when tube feeding preterm infants. Preterm infants have rapid growth, particularly of the brain, and high caloric needs. Enteral feeding is often poorly tolerated which may lead to growth failure and long-term neurodevelopmental impairment. Smell and taste are strong stimulators of digestion and metabolism. We hypothesise that regular smell and taste during tube feeding will improve weight z-scores of very preterm infants at discharge from hospital. Methods and analysis Taste is a randomised, unblinded two-centre trial. Infants born at Ethics and dissemination Human Research Ethics Committees of Mater Misericordiae (trial reference number: HREC/16/MHS/112) and the Royal Women’s Hospital (trial reference number: 17/21) last approved the trial protocol (version 4.2; Date: 18 December 2018) and recruitment commenced in May 2017 and November 2017, respectively. The trial results will be published in a peer-reviewed journal and will be presented at national and international conferences. Trial registration number ACTRN12617000583347.
- 1 November 2017
- Published by Elsevier in Early Human Development
- Vol. 114, 31-34
Smell and taste in the preterm infant
- 1 November 2017
- Published by Elsevier in Early Human Development
- Vol. 114, 31-34
Smell and taste in the preterm infant
- 1 December 2016
- Published by S. Karger AG in Neonatology
- Vol. 111 (3) , 260-266
Smell and Taste to Improve Nutrition in Very Preterm Infants: A Randomized Controlled Pilot Trial
Background: The perception of smell and taste, though present early in development, is not routinely considered in the care of preterm infants. Smell and taste are known to increase gut motility, insulin secretion, and the release of appetite, digestive and metabolic hormones. Objective: We aimed to investigate the effect of regular smell and taste on the time from birth to full enteral feeds, and the feasibility of the study protocol in very preterm infants. Methods: In a randomized controlled trial, infants Results: Infants in the treatment group (n = 28) and control group (n = 23) were born at a mean (SD) PA of 26.7 (1.5) and 27.2 (1.4) weeks, respectively. They reached full enteral feeds at a median (IQR) of 13.5 (10.0-19.0) and 15.5 (11.0-22.0) days, respectively. Survival analysis showed an adjusted hazard ratio of 1.63 (95% confidence interval 0.91-2.91; p = 0.10) for the effect on the time to establish full enteral feeds. Repeated-measures analysis indicated significant group differences in weight z scores at 36 weeks' PA and at discharge in favor of the intervention (p < 0.05). Conclusion: These data indicate that the smell and taste of milk may improve milk tolerance and weight in preterm infants. The role of regular smell and taste in promoting enteral nutrition and growth in preterm infants merits a larger trial powered to detect important outcomes.
- 1 December 2016
- Published by S. Karger AG in Neonatology
- Vol. 111 (3) , 260-266
Smell and Taste to Improve Nutrition in Very Preterm Infants: A Randomized Controlled Pilot Trial
Background: The perception of smell and taste, though present early in development, is not routinely considered in the care of preterm infants. Smell and taste are known to increase gut motility, insulin secretion, and the release of appetite, digestive and metabolic hormones. Objective: We aimed to investigate the effect of regular smell and taste on the time from birth to full enteral feeds, and the feasibility of the study protocol in very preterm infants. Methods: In a randomized controlled trial, infants Results: Infants in the treatment group (n = 28) and control group (n = 23) were born at a mean (SD) PA of 26.7 (1.5) and 27.2 (1.4) weeks, respectively. They reached full enteral feeds at a median (IQR) of 13.5 (10.0-19.0) and 15.5 (11.0-22.0) days, respectively. Survival analysis showed an adjusted hazard ratio of 1.63 (95% confidence interval 0.91-2.91; p = 0.10) for the effect on the time to establish full enteral feeds. Repeated-measures analysis indicated significant group differences in weight z scores at 36 weeks' PA and at discharge in favor of the intervention (p < 0.05). Conclusion: These data indicate that the smell and taste of milk may improve milk tolerance and weight in preterm infants. The role of regular smell and taste in promoting enteral nutrition and growth in preterm infants merits a larger trial powered to detect important outcomes.
- 1 February 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (2) , 477-479
Hemodynamic Effects of Nasal Continuous Positive Airway Pressure in Preterm Infants with Evolving Chronic Lung Disease, A Crossover Randomized Trial
- 1 February 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (2) , 477-479
Hemodynamic Effects of Nasal Continuous Positive Airway Pressure in Preterm Infants with Evolving Chronic Lung Disease, A Crossover Randomized Trial
- Open Access
- 1 November 2014
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 17 (4) , 146-149
Echocardiographic assessment of left ventricular outflow tract diameter in preterm infants
Introduction: Left ventricular output (LVO) measurement is an important part of the echocardiographic assessment of cardiac function in preterm infants. The accurate measurement of left ventricular outflow tract diameter (LVOD) is key to the calculation of LVO. Given the lack of an appropriate gold standard, we used right ventricular output (RVO) as the comparator and sought to identify the most accurate method of determining LVO in preterm infants. Methods: We studied stable preterm infants without significant cardiac shunts. LVOD was measured at the aortic valve, the aortic sinus and at the sinotubular junction. LVOs were calculated and the precision and accuracy of each was determined relative to the RVO using the Bland-Altman method. Results: 52 infants were included in this analysis. The mean difference between RVO and LVO was largest when LVOD was measured at the aortic valve and aortic sinus, +106 and −115 ml/kg/min, respectively, and smallest when measured at the sinotubular junction, 9 ml/kg/min. Limits of agreement between RVO and LVO were narrowest when LVOD was measured at the STJ. Conclusion: LVOD measurement at the sinotubular junction provides more precise and accurate measurement of LVO, in comparison to RVO, than measurement at the aortic valve or the aortic sinus.
- 1 November 2014
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 17 (4) , 146-149
Open AccessEchocardiographic assessment of left ventricular outflow tract diameter in preterm infants
Introduction: Left ventricular output (LVO) measurement is an important part of the echocardiographic assessment of cardiac function in preterm infants. The accurate measurement of left ventricular outflow tract diameter (LVOD) is key to the calculation of LVO. Given the lack of an appropriate gold standard, we used right ventricular output (RVO) as the comparator and sought to identify the most accurate method of determining LVO in preterm infants. Methods: We studied stable preterm infants without significant cardiac shunts. LVOD was measured at the aortic valve, the aortic sinus and at the sinotubular junction. LVOs were calculated and the precision and accuracy of each was determined relative to the RVO using the Bland-Altman method. Results: 52 infants were included in this analysis. The mean difference between RVO and LVO was largest when LVOD was measured at the aortic valve and aortic sinus, +106 and −115 ml/kg/min, respectively, and smallest when measured at the sinotubular junction, 9 ml/kg/min. Limits of agreement between RVO and LVO were narrowest when LVOD was measured at the STJ. Conclusion: LVOD measurement at the sinotubular junction provides more precise and accurate measurement of LVO, in comparison to RVO, than measurement at the aortic valve or the aortic sinus.
- 1 April 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (4) , 726-729
The Effects of Nasal Continuous Positive Airway Pressure on Cardiac Function in Premature Infants with Minimal Lung Disease: A Crossover Randomized Trial
- 1 April 2014
- Published by Elsevier in The Journal of Pediatrics
- Vol. 164 (4) , 726-729
The Effects of Nasal Continuous Positive Airway Pressure on Cardiac Function in Premature Infants with Minimal Lung Disease: A Crossover Randomized Trial
- 1 August 2008
- Published by SAGE Publications in Cephalalgia
- Vol. 28 (8) , 887-891
CACNA1A Mutation Linking Hemiplegic Migraine and Alternating Hemiplegia of Childhood
Familial hemiplegic migraine (FHM) and alternating hemiplegia of childhood (AHC) are severe neurological disorders that share clinical features. Therefore, FHM genes are candidates for AHC. We performed mutation analysis in the CACNA1A gene in a monozygotic twin pair with clinical features overlapping with both AHC and FHM and identified a novel de novo CACNA1A mutation. We provide the first evidence that a CACNA1A mutation can cause atypical AHC, indicating an overlap of molecular mechanisms causing AHC and FHM. These results also suggest that CACNA1A mutation scanning is indicated in patients with a severe neurological phenotype that includes paroxysmal (alternating) hemiplegia.
- 1 August 2008
- Published by SAGE Publications in Cephalalgia
- Vol. 28 (8) , 887-891
CACNA1A Mutation Linking Hemiplegic Migraine and Alternating Hemiplegia of Childhood
Familial hemiplegic migraine (FHM) and alternating hemiplegia of childhood (AHC) are severe neurological disorders that share clinical features. Therefore, FHM genes are candidates for AHC. We performed mutation analysis in the CACNA1A gene in a monozygotic twin pair with clinical features overlapping with both AHC and FHM and identified a novel de novo CACNA1A mutation. We provide the first evidence that a CACNA1A mutation can cause atypical AHC, indicating an overlap of molecular mechanisms causing AHC and FHM. These results also suggest that CACNA1A mutation scanning is indicated in patients with a severe neurological phenotype that includes paroxysmal (alternating) hemiplegia.